ARQT Arcutis Biotherapeutics Inc

The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

WESTLAKE VILLAGE, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 21,000 restricted stock units of Arcutis' ...

Arcutis Biotherapeutics ( NASDAQ:ARQT ) , a dermatology-focused pharmaceutical company, reported earnings results on August 6, 2025. Highlights included strong revenue growth and improved earnings, significantly outperforming Wall Street expectations, with GAAP revenue of $81.5 million and GAAP ...

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.